Estudio de la actividad antimicrobiana de una crema dental en gel con EDS frente a Streptococcus mutans y Actinobacillus actinomycetemcomitans / A study of the antimicrobial activity of a EDS-containing dental gel against Streptococcus mutans and Actinobacillus actinomycetemcomitans

Determinar la actividad antimicrobiana de la pasta en gel de dientes contra dos microorganismos: mutans Streptococccus y Actinobacillus actinomycetemcomitans...

Nivel de satisfacción con pamidronato disódico en el tratamiento de osteogénesis imperfecta: trabajo realizado en el Hospital Ortopédico Infantil Caracas Venezuela / Level of satisfaction with pamidronate disodium in the treatment of osteogenesis imperfecta: work Hospital Ortopédico Infantil Caracas Venezuela

Se realizó un estudio descriptivo, prospectivo, de tipo transversal para determinar el nivel de satisfacción en 101 pacientes con Osteogénesis Imperfecta en el tratamiento con Pamidronato. Se contactaron por encuesta vía telefónica a 52 pacientes quienes contaban con al menos dos ciclos de tratamiento.De 505 fracturas reportadas, el 71% se produjeron previas al tratamiento, evidenciándose disminución del 42% de fracturas. 69 % de los pacientes no refieren dolor posterior al tratamiento en comparación con el 27% que no refieren dolor previo al tratamiento. El porcentaje de pacientes capaces de caminar de manera independiente aumentó 21%, disminuyendo 31% de paciente confinados al lecho o silla de ruedas. El porcentaje de mejoría, conformidad y recomendación del tratamiento es favorable en casi 100% de los entrevistados. El tratamiento con Pamidronato mejora la calidad de vida de los pacientes con Osteogénesis Imperfecta.

We present a descriptive study to evaluate the level of satisfaction in 101 patients with Osteogenesis Imperfecta in treatment with Pamidronato. We contact 52 patient for an enquire by telephone, who have 2 or more ciclos of treatment. From 505 fractures report, the 71% was until treatment, we found disminution of 42% of fractures. 69% of patients don’t refer pain after treatment in comparison with the 27% that do not refer pain until treatment. The porcent of patients capables of walk independent increase 21%, decrease 31% of patients that can not walk. The porcent of improvement, conformity and recomendation of treatment is good in also 100% of interview. The treatment with Pamidronato improve the life quality in the patients with Osteogenesis Imperfecta.

Comparative therapeutic use of Risedronate and Calcarea phosphorica - allopathy versus homeopathy - in bone repair in castrated rats / Comparação do uso terapêutico de Risedronato e Calcarea phosphorica - alopatia versus homeopatia - no reparo ósseo em ratos castrados

Osteoporosis, a disease characterized by progressive bone loss, has been the target of several studies in the past few years. It results in a much higher risk for fractures and might cause slower bone lesion healing. The aim of this work was to study the effects of Risedronate (allopathic medicine) and Calcarea phosphorica 6CH (homeopathic medicine) on the repair of bone lesions in male rats with osteoporosis induced by castration. Eighty-four three-month-old rats were used divided into four groups of twenty-one animals each. Three groups where castrated and one group was submitted to Sham surgery. One month later, cortical lesions were made in all animals' tibiae and, after one day, the different experimental treatments began according to the following groups: CR - castrated/Risedronate (1 mg/kg/day); CCp - castrated/Calcarea phosphorica 6CH (3 drops/day); CP - castrated/placebo and SP - Sham/placebo. The animals were sacrificed at seven, fourteen and twenty-eight days after the beginning of the treatments and had their tibiae removed. Digital radiographs of the tibiae were taken and analyzed in order to evaluate the optical density of the defect area. Then, they were decalcified and processed for histological and histomorphometrical analysis. The data were submitted to ANOVA, and to the Tukey and Dunnett tests (5 percent). The allopathic and homeopathic treatments led to different bone formation as regards remodeling and maturation aspects. Further research is necessary to access the resistance and quality of the newly formed bone.

A osteoporose, doença caracterizada pela perda de massa óssea, tem sido alvo de estudos nos últimos anos. Fraturas decorrentes da osteoporose são muito comuns e podem apresentar consolidação mais lenta. O objetivo deste trabalho foi avaliar o efeito do risedronato (medicamento alopático) e da Calcarea phosphorica 6CH (medicamento homeopático) no reparo de lesões ósseas em ratos com osteoporose induzida por castração. Para tanto, foram utilizados oitenta e quatro ratos, com três meses de idade, separados em quatro grupos de vinte e um animais, sendo três grupos submetidos à castração e um grupo a falsa cirurgia ("Sham"). Um mês após a cirurgia, foram realizadas lesões corticais na tíbia de todos os animais e, a partir do dia seguinte, os tratamentos experimentais foram iniciados de acordo com os seguintes grupos: CR - castrado/risedronato (1 mg/kg/dia); CCp - castrado/Calcarea phosphorica 6CH (três gotas/dia); CP - castrado/placebo e SP - "sham"/placebo. Os animais foram sacrificados aos sete, catorze e vinte e oito dias após o início do tratamento e as tíbias foram removidas. Radiografias digitais foram realizadas e avaliadas para obter a densidade óptica na área do defeito. Em seguida, foram descalcificadas e processadas para análise histológica e histomorfométrica. Os dados foram submetidos a ANOVA e aos testes de Tukey e Dunnett (5 por cento). Os tratamentos alopático e homeopático levaram a formação óssea de aspecto diferente considerando a remodelação e maturação. Mais pesquisas são necessárias para avaliar a resistência e qualidade do osso neoformado.

Subcutaneous fat necrosis with hypercalcemia.

Subcutaneous fat necrosis of the newborn (SCFN) is an uncommon condition and may be complicated by hypercalcemia. A 28-day-old neonate, presenting with SCFN, hypercalcemia and nephrocalcinosis was managed with intravenous saline followed by furosemide, oral prednisolone, potassium citrate and etidronate.

Efficacy and safety of risedronate sodium in treatment of postmenopausal osteoporosis / 华中科技大学学报（医学）（英德文版）

To evaluate the efficacy and safety of risedronate sodium in treatment of postmenopausal osteoporosis, one-year randomized, double blind clinical trial was performed among 54 women with postmenopausal osteoporosis. The changes were compared in bone mineral density (BMD), bone metabolism markers and adverse events after 12 months oral administration of risedronate sodium. BMD was measured by dual energy X-ray absorptionmetry (DEXA) and bone turnover marker was detected. The results showed that there was a significant increase in BMD of the lumbar spine (3.29% +/- 1.18%, 4.51% +/- 1.64% respectively) after 6 and 12 months in the risedronate treatment group versus placebo control group (-0.62% +/- 0.24%, 0.48% +/- 0.18% respectively). Bone turnover was decreased to a stable nadir over 6 and 12 months for resorption markers [N-Telopeptide (NTx), P < 0.05] and over 12 months for formation marker (ALP, P < 0.05; BGP, P < 0.05). The safety profile of risedronate sodium was similar to that of placebo. There were no trends toward increased frequency of any adverse experience except for gastrointestinal symptoms (7.1%), rash (7.1%) and hematuria (3.6%), which were usually mild, transient, and resolved with continued treatment. It was concluded that risedronate was an efficacious and safe drug in treatment of postmenopausal osteoporosis.

Fibrodysplasia ossificans progressiva: case report

Fibrodysplasia ossificans progressiva is a rare genetic disease characterized by widespread soft tissue ossification and congenital stigmata of the extremities. We report on a male child followed for ten years since the age of 3 years and 9 months, when the diagnosis was made. He was born with bilateral hypoplasic hallux valgus and ventricular septal defect, corrected by transsternal approach when 32 months old. Restriction of neck mobility followed and foci of ectopic ossification appeared. Four crises of disease exacerbation were treated with oral prednisone and/or other antiinflammatory drugs. Sodium etidronate 5 to 10 mg/kg/day was prescribed intermittently during about six years but was discontinued due to osteopenia. The disease course has been relentless, with severe movement restriction including the chest wall. A review showed few similar case reports in the Brazilian literature. We revisit the criteria for diagnosis and the essentials of management and treatment.

Enfermedad ósea de Paget: diagnóstico diferencial de lesiones osteolíticas: caso clínico / Paget disease of the bone: differential diagnosis of osteolytic lesions: report of 1 case

We report a 48 years old female with Paget's disease of the bone who consulted for leg pain. After exhaustive examination a magnetic nuclear resonance revealed a 7 mm intradural schwannoma that was resected without improvement. Four years later, with generalized, progressive bone pains, several osteolytic rib lesions were detected. A bone scintigraphy showed extensive areas of hyperfixation of Tc99 DPM. Biochemical tests were normal with exception of very high serum alkaline phosphatases. Looking for some neoplastic disease, a breast nodule was detected by mammography. Biopsy demonstrated benign disease. Finally, a rib lesion biopsy disclosed diagnosis of Paget's disease of the bone. Treatment with calcitonin, etidronate and vitamin D resulted in partial clinical improvement, reduction of abnormal isotope hyperfixation in bone scintigraphy and of serum alkaline phosphatase levels

Miositis osificante progresiva congénita: A propósito de un caso revisión de la literatura / Congenital progressive myositis osifficant: Apropos of a case and review of literature

La miositis osificante progresiva es una enfermedad rara caracterizada por la formación de áreas de calcificación en el tejido conectivo intersticial de músculos, tendones, ligamentos, fascias y aponeurosis que pueden ser detectadas radiológicamente. Aunque las manifestaciones de la enfermedad pueden no ser evidentes hasta después de los diez años de vida, está asociada a ciertas anomalías congénitas como acortamiento de los pulgares hallux valgus y clinodactilia. El curso de la enfermedad es progresivo causando anquilosis, invalidez e incluso la muerte. El tratamiento es discutido, en la actualidad el etidronato disódico y la prednisona son los medicamentos más utilizados con resultados poco alentadores. Presentamos el caso de una niña de 2 años y 10 meses con manifestaciones clínicas de un año de evolución, nódulos calcificantes en diferentes sitios del cuerpo y limitación severa a la movilización del cuello y cintura escapular, inicialmente diagnosticada como dermatomiositis. Se enfatizan los hallazgos radiológicos y anatomopatológicos, así como la importancia de evitar los traumatismos y procedimientos invasivos como medida preventiva en estos niños

Fibrodysplasia ossificans progressiva

Fibrodisplasia (miosite) ossificante progressiva (FOF) é doença rara, de herança autossômica dominante, na qual ocorre ossificaçäo ectópica progressiva e malformaçäo esquelética, principalmente no tecido conectivo dos músculos. O diagnóstico é baseado nos achados clínicos e demonstraçäo radiológica das malformaçöes esqueléticas. Relatamos o caso de uma menina de 5 anos de idade com FOF

Doença de Paget: estudo de cinco casos tratados com etidronato dissódico / Paget's disease: study of 5 cases treated with etidronate disodium

Cinco pacientes com doença de Paget foram tratados com etidronato dissódico. Avaliados após seis meses de tratamento, apresentaram melhora clínica, sendo nítido o efeito analgésico. Houve reduçäo na captaçäo de radioisótopos observada pela cintilografia óssea, assim como nos níveis de fosfatase alcalina. Os autores discutem o valor do etidronato dissódico como tratamento da doença de Paget e o uso de cintilografia óssea para acompanhamento da resposta terapêutica